» » »

Aspirin for Colorectal Cancer Durham NC

Taking aspirin might not only reduce the risk of getting colorectal cancer, but it also might lower the odds of dying if you have it, new research suggests. People with colorectal cancer#日# who took aspirin regularly had a 29 percent lower risk for death from the cancer and a 21 percent lower risk for death from other causes, according to the research, reported in the Aug. 12 issue of the Journal of the American Medical Association.

Douglas Rivera, MD
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Ngocdiep Thi Le, MD
(919) 681-6816
3829 Duke South Red Zone DUMC 3841,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Stanford Univ Sch Of Med, Stanford Ca 94305
Graduation Year: 2000

Data Provided by:
Michael Colvin
(919) 620-4467
2100 Erwin Rd
Durham, NC
Specialty
Hematology / Oncology

Data Provided by:
Shiaowen David Hsu
(919) 684-8111
2100 Erwin Rd
Durham, NC
Specialty
Hematology / Oncology

Data Provided by:
Timothy Alan Driscoll, MD
Box #2916 Duke University Medical Cntr,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Oh State Univ Coll Of Med, Columbus Oh 43210
Graduation Year: 1990

Data Provided by:
Thomas Roberts Kinney, MD
(919) 489-9704
Box 3462,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Duke Univ Sch Of Med, Durham Nc 27710
Graduation Year: 1970

Data Provided by:
David M Conigli, MR
(919) 681-3162
DUMC Box 3848 CFM-PAP,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Pearl H Seo, MD
(919) 668-1748
DUMC 3893,
Durham, NC
Specialties
Oncology (Cancer), Geriatric Medicine-Internal Medicine
Gender
Female
Education
Medical School: Cornell Univ Med Coll, New York Ny 10021
Graduation Year: 1995
Hospital
Hospital: Duke University Med Ctr, Durham, Nc; Veterans Affairs Med Ctr, Durham, Nc
Group Practice: Duke University Medical Center

Data Provided by:
Yiping Yang, MD
(919) 668-0932
DUMC Box 3502,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Zhejiiang Med Univ, Hangzhou, Zhejiang, China
Graduation Year: 1985

Data Provided by:
Gordana Vlahovic, MD
PO Box 3335 Rm 25164,
Durham, NC
Specialties
Oncology (Cancer)
Gender
Female
Education
Medical School: Univ Of Zagreb, Med Fak, Zagreb, Croatia
Graduation Year: 1987

Data Provided by:
Data Provided by:

Aspirin for Colorectal Cancer

Provided By:

Taking aspirin might not only reduce the risk of getting colorectal cancer, but it also might lower the odds of dying if you have it, new research suggests.

People with colorectal cancer who took aspirin regularly had a 29 percent lower risk for death from the cancer and a 21 percent lower risk for death from other causes, according to the research, reported in the Aug. 12 issue of the Journal of the American Medical Association.

After an average of about 12 years, 35 percent of the 549 people with colorectal cancer who took aspirin had died. That included about 15 percent whose death was attributed to the cancer.

Among 730 people with colorectal cancer who did not take aspirin, 39 percent had died, including 19 percent from the cancer.

The overall five-year survival rate was 88 percent for people who used aspirin, compared with 83 percent for those who did not. The 10-year survival rate was 74 percent for aspirin users and 69 percent for those who didn't use aspirin.

Researchers used data on 1,279 men and women with stage 1, 2 or 3 nonmetastatic colorectal cancer who were participating in two large studies, the Nurses Health Study that began in 1980 and the Health Professionals Follow-up Study that began in 1986.

"It's a pretty significant benefit and does suggest aspirin may have a role in treatment of patients with established colorectal cancer as well as for the prevention of developing initial tumors," said the study's lead author, Dr. Andrew Chan, a gastroenterologist at Massachusetts General Hospital and an assistant professor of medicine at Harvard Medical School.

Among 719 participants who had not used use aspirin before their cancer diagnosis, starting to take it once they'd been diagnosed was associated with a 47 percent lower risk for dying from the cancer and a 32 percent lower risk for dying prematurely from any cause.

The benefits linked to aspirin were especially evident among people with COX-2 positive tumors.

Previous research has shown that aspirin might reduce the chances of developing colorectal cancer tumors by inhibiting cyclooxygenase (COX-2) enzyme, Chan said. COX-2, which contributes to inflammation and cell proliferation, is overproduced in about 65 to 80 percent of human colorectal cancers, he said.

Researchers were able to test for the COX-2 overproduction in 459 people. Among those with what are known as "COX-2 positive" tumors, regular aspirin use after diagnosis was associated with a 61 percent lower risk for dying from colorectal cancer and 38 percent lower risk for premature death from any cause.

However, those who had "COX-2 negative" tumors and who took aspirin did not show decreased mortality, according to the study.

Nor did the researchers find much benefit for people who had been using aspirin before their cancer diagnosis. For them, continuing to take aspirin during and after their cancer treatment was not associated with a significant reduction in colorectal survival, Chan said.

"What that suggests is that those who developed cancer despite being on aspirin were probably developing cancers that were relatively resistant to aspirin," he said. "There are some tumors that are responsive to the effects of aspirin and some that are not."

Despite mounting evidence of aspirin's potential cancer-fighting properties, Chan stopped short of recommending that it be used to prevent or treat colorectal cancer.

Aspirin can cause side effects, including gastrointestinal bleeding. Further studies, including placebo-controlled trials of aspirin and other anti-inflammatory agents, are needed, he said.

"What we need before we make definitive clinical recommendations for all patients with colorectal cancer are large-scale, randomized, controlled trials to demonstrate benefits," Chan said. "That's the gold standard."

Dr. Alfred Neugut, a professor of medicine and epidemiology at Columbia University, who wrote an accompanying editorial, called the results "provocative."

"What makes this study more convincing than the average study was they measured COX-2 and were able to show that the aspirin helped those who were 'COX-2 positive' but had no significant effect on 'COX-2 negative' patients," Neugut said. "That's what's so elegant."

Neugut agreed that it was too soon to recommend aspirin as a means of preventing colorectal cancer. But an ongoing clinical trial sponsored by the National Cancer Center of Singapore might provide the necessary evidence, he added.

"Even though the study is very, very strong, most doctors would say we need a randomized trial," Neugut said. "If you're taking aspirin for cardiovascular disease prevention, you are probably getting a bonus in terms of it preventing colon cancer, but I wouldn't recommend it solely for colon cancer prevention."

More information

The American Cancer Society has more on colorectal cancer.

SOURCES: Andrew Chan, M.D., M.P.H., assistant professor, medicine, Harvard Medical School, and gastroenterologist, Massachusetts General Hospital, Boston; Alfred I. Neugut, M.D., Ph.D., professor, medicine and epidemiology, Herbert Irving Comprehensive Cancer Center, Columbia University, New York City; Aug. 12, 2009, Journal of the American Medical Association

Author: By Jennifer Thomas
HealthDay Reporter

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com